Pathophysiology of Peyronie’s disease

International Journal of Impotence Research

Volumn 14, Issue 5, 2002, Pages 406-410

  Moreland, R B ^a   Nehra, A ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Genetics; Peyronie's; TGF 1

Indexed keywords

PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR B; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2;

CORPUS CAVERNOSUM; ERECTILE DYSFUNCTION; GENETIC PREDISPOSITION; HISTOPATHOLOGY; HLA TYPING; HUMAN; INFLAMMATION; MALE; MICROVASCULATURE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PEYRONIE DISEASE; PRIORITY JOURNAL; REVIEW; TISSUE INJURY; TUNICA ALBUGINEA; WOUND HEALING;

BLOOD VESSELS; FREE RADICALS; HUMANS; INCIDENCE; MALE; OXIDATIVE STRESS; PENILE INDURATION; PENIS; STRESS, MECHANICAL; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; WOUNDS AND INJURIES;

EID: 0036803395     PISSN: 09559930     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijir.3900875     Document Type: Review

References (50)

1. Gelbard M. Peyronie's disease. In: Hashmat AI Das S eds. The Penis. Lea and Febiger: Philadelphia, 1993; pp 244-365.
2. Carrier S, Lue TF. For Peyronie's disease, act conservatively. Contemporary Urol 1994; 9: 54-65.
3. Pryor JP. The management of Peyronie's disease. In: Porst H, ed. Penile Disorders Proceedings of the International Symposium on Penile Disorders, Hamburg, Germany, 26-27 January 1996. Springer Verlag, Berlin, 1997, pp 75-86.
4. Devine CJ, Horton CE. Peyronie's disease. Clin Plast Surg 1988; 15: 405-409.
5. Jarow JP, Lowe FC. Penile trauma: An etiologic factor in Peyronie's disease and erectile dysfunction. J Urol 1997; 158: 1388-1390.
6. Devine CJ, Somers KD, Jordan GH, Schlossberg SM. Proposal: Trauma as a cause of Peyronie's lesion. J Urol 1997; 157: 285-290.
7. Vande Berg JS et al. Mechanisms of calcification in Peyronie's disease. J Urol 1982; 127: 52-54.
8. Krane RJ. The treatment of loss of penile rigidity associated with Peyronie's disease. Scand J Urol Nephrol Suppl 1997; 179: 147-150.
9. Gasior BL et al. Plaque-associated corporal veno-occlusive dysfunction in idiopathic Peyronie's disease: A pharmacocavernosometric and pharmacocavernosographic study. World J Urol 1990; 8: 90-97.
10. Lopez JA, Jarow JP. Penile vascular evaluation of men with Peyronie's disease. J Urol 1993; 149: 53-55.
11. Lyles KW et al. Peyronie's disease is associated with Paget's disease of the bone. J Bone Miner Res 1997; 12: 929-934.
12. Nyberg LM, Bias WB, Hochberg MC, Walsh PC. Identification of an inherited form of Peyronie's disease with an autosomal dominant inheritance and association with Dupuytren's contracture and histocompatability B7 cross-reactive antigens. J Urol 1982; 128: 48-52.
13. Ralph DJ et al. The genetic and bacteriological aspects of Peyronie's disease. J Urol 1997; 157: 291-294.
14. Leffell MS. Is there an immunogenetic basis for Peyronie's disease? J Urol 1997; 157: 295-297.
15. Schiavino D et al. Immunologic findings in Peyronie's disease: A controlled study. Urology 1997; 50: 764-768.
16. Stewart S, Malto M, Sandberg L, Colburn KK. Increased serum levels of anti-elastin antibodies in patients with Peyronie's disease. J Urol 1994; 152: 105-106.
17. Diegelmann RF. Cellular and biochemical aspects of normal and abnormal wound healing: An overview. J Urol 1997; 157: 298-302.
18. Lindsay MB et al. The incidence of Peyronie's disease in Rochester, Minnesota, 1950 through 1984. J Urol 1991; 146: 1007-1009.
19. Smith BH. Subclinical Peyronie's disease. Am J Clin Pathol 1969; 52: 385-390.
20. Hsu G-L et al. The three-dimensional structure of the tunica albuginea: Anatomical and structural levels. Int J Impot Res 1992; 4: 117-132.
21. Hsu G-L et al. Anatomy and strength of the tunica albuginea: Its relevance to penile prosthesis extrusion. J Urol 1994; 151: 1205-1208.
22. Brock G et al. The anatomy of the tunica albuginea in the normal penis and in Peyronie's disease. J Urol 1997; 157: 276-281.
23. Devine CJ. International Conference on Peyronie's Disease: Introduction. J Urol 1997; 157: 272-275.
24. Gentile V et al. Ultrastructural and immunohistochemical characterization of the tunica albuginea in Peyronie's disease and veno-occlusive function. J Androl 1996; 17: 96-103.
25. Somers KD et al. Isolation and characterization of collagen in Peyronie's disease. J Urol 1989; 141: 629-631.
26. Udelson D et al. Engineering analysis of penile hemodynamic and structural dynamic relationships: Part I. Clinical implications of penile tissue mechanical properties. Int J Impot Res 1998; 10: 15-24.
27. Akkus E et al. Structural alterations in the tunica albuginea of the penis: Impact of Peyronie's disease, ageing and impotence. Br J Urol 1997; 79: 47-53.
28. van de Water L. Mechanisms by which fibrin and fibronectin appear in healing wounds: Implications for Peyronie's disease. J Urol 1997; 157: 306-310.
29. Somers KD, Dawson DM. Fibrin deposition in Peyronie's disease plaque. J Urol 1997; 157: 311-315.
30. Border WA, Ruoslahti E. Transforming growth factor-β in disease: The dark side of tissue repair. J Clin Inv 1992; 90: 1-7.
31. Border WA, Noble NA. Transforming growth factor-β in tissue fibrosis. N Engl J Med 1994; 331: 1286-1291.
32. Moreland RB. Is hypoxemia associated with penile fibrosis? Int J Impot Res 1998; 10: 113-120.
33. El-Sakka AI et al. Peyronie's disease is associated with an increase in transforming growth factor-beta protein expression. J Urol 1997; 158: 1391-1394.
34. El-Sakka AI et al. An animal model of Peyronie's-like condition associated with an increase in transforming growth factor-beta mRNA and protein expression. J Urol 1997; 158: 2284-2290.
35. El-Sakka AI et al. Histological and ultrastructural alterations in an animal model of Peyronie's disease. Br J Urol 1998; 81: 445-452.
36. Poli G, Parola M. Oxidative damage and fibrogenesis. Free Radical Biol Med 1997; 22: 287-305.
37. Scardino PL, Scott WW. The use of tocopherols in the treatment of Peyronie's disease. Ann NY Acad Sci 1949; 52: 390-394.
38. Zarafonetis CJD, Horran TM. Treatment of Peyronie's disease with potassium para-aminobenzoate (POTABA). J Urol 1959; 81: 770-772.
39. Bartsch G, Menander-Huber KB, Huber W, Marberger H. Orgotein, a new drug for the treatment of Peyronie's disease. Eur J Rheumatol Inflamm 1981; 4: 250-259.
40. Ludwig G. Evaluation of conservative therapeutic approaches to Peyronie's disease (fibrotic induration of the penis). Urol Int 1991; 47: 236-239.
41. Primus G. Orgotein in the treatment of plastic induration of the penis (Peyronie's disease). Int Urol Nephrol 1993; 25: 169-172.
42. Lenk S, Schonberger B. Penile deviation-our therapeutic concept. Acta Chir Hung 1994; 34: 189-194.
43. Flohe L. Superoxide dismutase for therapeutic use: Clinical experience, dead ends and hopes. Mol Cell Biochem 1988; 84: 123-131.
44. Levine LA. Treatment of Peyronie's disease with intralesional verapamil injection. J Urol 1997; 158: 1395-1399.
45. Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie's disease plaque: A long-term single blind study. Urology 1998; 51: 620-626.
46. Akkus E et al. Is colchicine effective in Peyronie's disease? A pilot study. Urology 1994; 44: 291-295.
47. Gelbard MK, James K, Riach P, Dorey F. Collagenase versus placebo in the treatment of Peyronie's disease: A double-blind study. J Urol 1993; 149: 56-58.
48. Judge JS, Wisniewski ZS. Intralesional interferon in the treatment of Peyronie's disease: A pilot study. Br J Urol 1997; 79: 40-42.
49. Polat O et al. Peyronie's disease: Intralesional treatment with interferon alpha 2-A and evaluation of results by magnetic resonance imaging. Int Urol Nephrol 1997; 29: 465-471.
50. Ralph DJ, Brooks MD, Botazzo GF, Pryor JP. The treatment of Peyronie's disease with tamoxifen. Br J Urol 1992; 70: 648-651.